Genmab (GMAB) said Monday that data from a phase 1/2 Rainfol-01 trial demonstrated that rinatabart sesutecan in combination with bevacizumab was tolerable and showed no new safety signals in patients with advanced ovarian cancer.

The most common treatment-emergent adverse events, or TAEs, under the 40-patient trial included nausea, fatigue, anemia, and neutropenia. Serious TAEs occurred in six patients, while TAEs leading to rinatabart sesutecan dose reductions occurred in 11 patients and bevacizumab discontinuation occurred in two patients, the company said.